오지수

This profile gathers the share dealings of 오지수 in 메타바이오메드, where the filings describe the role as chief executive. In total, 17 filings cover trades dated from 15 December 2021 to 12 June 2026.

The open-market record is one-sided, with 17 purchases worth €16k and not one sale. The totals exclude 14 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. 2026 to date brings 7 purchases and no sales.

Half of the purchases are above €7,431 and half below. Measured against the company's value, the median purchase equals 0.011% of market capitalisation, across 3 purchases where it is known. Across 9 purchases, this insider has always bought alone, with no colleague buying within 30 days.

The record was last updated on 12 June 2026 with an open-market purchase in 메타바이오메드. The median gap between a trade and its publication by DART (FSS) is 13 days. That lag is the time during which only the insider knows about the trade. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.